Economic evaluation of Personalized Medicine (PM) is growing, but there are several unsolved challenges that require… Read more
- Study: Obstacles Remain for PRO Data
- SHYFT'S Berger Talks Path to Stronger RWE
- What are the Unsolved Challenges in Economic Evaluation for Personalized Medicine?
- PhRMA's Lori Reilly Testifies at Senate Hearing
- The Future of Market Access in the U.S.
- Robinson: 'New York is Big Pharma Battleground'
- Kristensen, Reed and Watkins Discuss HTA
- Is Cybersecurity on Backburner for HCOs?
- States Putting Foot Down on High Drug Prices
- New Avella Program Aims to Engage, Support Patients
David Robinson with lohud calls New York a "big pharma battleground," citing a problematic relationship between pharma's "boom-or-bust" history and… Read more
According to a survey conducted by the HealthCare Executive Group, most health care organizations seem more focused on reimbursement than… Read more
According to a study presented during the Academy of Managed Care Pharmacy's Nexus conference, industry professionals are hesitant to put their full… Read more
SHYFT Analytics Real World Evidence Advisory Board Chair Marc Berger in an interview discussed how the use of real-world evidence continues to evolve… Read more
Pharmaceutical Research and Manufacturers of America Executive Vice President for Policy, Research and Membership Lori Reilly testified Tuesday at a… Read more